PATENT CLAIM ANALYSIS

Application Number: 16171124
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-06
Patent Classification: ["546", "069000"]

Abstract:
Provided herein are ergoline compounds and pharmaceutical compositions thereof. In some embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT 1A , 5-HT 1B  and 5-HT 1D  receptors without agonizing the 5-HT 2B  receptor using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the 5-HT 2B  adrenergic alpha 2A  and/or the alpha 2B  receptors using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the D2 and D3 receptor using the compounds and pharmaceutical compositions disclosed herein.

Claim (Index 33):
The method of  claim 24 , wherein R 8  is methyl.

Metadata:
- Claim Count in Document: 44.0
- Percentile: 97.0
- Lexical Diversity: 2.86275
- Patent Class: 546.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15943714', '16016474', '15001252', '15448951', '15449018']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8278688504338089
- 35 USC 102 Novelty (BERT): 0.5289339134287431
- Combined Prediction Score: 0.7979753567333023
- Mean Citation Score: 362.98652
- Max Citation Score: 375.36508
- Similarity Product: 236.777700431118

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test